TauRx

Pharmaceutical ManufacturingScotland, United Kingdom51-200 Employees

TauRx was established to address one of the world’s biggest challenges – beating Alzheimer’s disease and other degenerative brain disorders through a completely new approach. A leader in Alzheimer’s research, the company’s mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative disorders.  

TauRx’s strong research team, supported through cooperative relationships with multiple academic institutions around the world, has focussed on the tau pathway, believed to be one of the critical causes of neurodegeneration in the brain. The company’s novel tau aggregation inhibitors (TAIs) target the formation of tau protein ‘tangles’ in the brain, with its lead compound having shown strong pharmacological effect in early trials for participants with mild and moderate Alzheimer's disease. 

The experimental drug has shown to inhibit aggregation of tau, synuclein, TPD-43 and huntingtin proteins. It is currently in development for the treatment and prevention of Alzheimer’s disease, with a pivotal phase 3 clinical trial in progress and results recently disclosed. 

Additionally, TauRx works closely with joint venture company Genting TauRx Diagnostics Ltd (GTD) in the development of ground-breaking new diagnostic tools and blood tests for dementia, which will help transform the treatment pathway for those affected, ensure efficient and early diagnosis and enhance access to treatment and care.   

TauRx Therapeutics Management Ltd is incorporated in Scotland with primary research and operations in Aberdeen.

Sign up for free to view info

Email Format Employee directory